Ondansetron for the Treatment of Methamphetamine Dependence - 1

National Institute on Drug Abuse (NIDA)154 enrolled

Overview

The purpose of this study is to assess ondansetron for the treatment of methamphetamine dependence.

This study was designed to be a preliminary assessment of the efficacy and safety of 3-wide range doses of ondansetron (0.25, 1.0 and 4.0 mg taken orally twice per day) to reduce methamphetamine use in subjects with methamphetamine dependence and to determine the optimal dose of ondansetron.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

154

Conditions

Amphetamine-Related Disorders

Interventions

OndansetronDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: 18 years of age. Treatment seeking for meth dependence. Exclusion Criteria: Please contact site director for more details.

Locations (6)

South Bay Treatment Center

Chula Vista, California, United States

Matrix Institute on Addictions

Costa Mesa, California, United States

John A. Burns School of Medicine

Honolulu, Hawaii, United States

Powell Chemical Dependency Center

Des Moines, Iowa, United States

Outcomes

Primary Outcomes

Clinicial improvement

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.